|
 The Oxford Vaccine Group's director, Andrew Pollard, said in a media
briefing there were "lots of cases" of infections in its Phase III
trial in Britain, Brazil and South Africa.
The first two sets of interim data from vaccine trials from Pfizer <PFE.N>
and BioNTech <BNTX.O> last week and Moderna <MRNA.O> on Monday were
released after more than 90 infections among volunteers.
Pfizer had planned to publish initial data after about 60
infections, but it exceeded its target after the big jump in
infections recently in the United States.
Pollard's comments came after data published on Thursday showed the
Oxford/AstraZeneca vaccine in Phase II studies produced a strong
immune response in older adults, suggesting that those at higher
risk of serious illness and death from COVID-19 could be protected.
[to top of second column] |
Pollard said there was no attempt to release the study in the same week as those
companies' data, the first from late-stage vaccine trials, but rather the study
happened to be ready for publication.
Earlier on Thursday, he said he expected Phase III data to be released by
Christmas.
The Phase III results showing efficacy of the vaccine will be released via
AstraZeneca, in the same way they have been published by other drugmakers over
the past week or so, Pollard said.
He said the trial would also publish the findings in a peer-reviewed medical
journal but initial data would likely be released before then.
(Reporting by Alistair Smout and Kate Kelland; Writing by Josephine Mason;
Editing by Alex Richardson and Nick Macfie)
[© 2020 Thomson Reuters. All rights
reserved.] Copyright 2020 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
